ZIOPHARM Oncology (ZIOP) Earning Somewhat Positive News Coverage, Study Shows

News stories about ZIOPHARM Oncology (NASDAQ:ZIOP) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.0825691412309 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, HC Wainwright assumed coverage on shares of ZIOPHARM Oncology in a report on Thursday, June 1st. They set a “buy” rating and a $9.50 price objective on the stock. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. ZIOPHARM Oncology has an average rating of “Hold” and an average target price of $13.17.

Shares of ZIOPHARM Oncology (NASDAQ ZIOP) traded down 3.11% during mid-day trading on Friday, hitting $4.99. 1,324,948 shares of the stock traded hands. ZIOPHARM Oncology has a one year low of $4.84 and a one year high of $7.88. The firm’s market capitalization is $701.75 million. The company’s 50 day moving average is $5.79 and its 200 day moving average is $6.32.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same period in the prior year, the business earned ($1.01) earnings per share. ZIOPHARM Oncology’s quarterly revenue was down 5.9% compared to the same quarter last year. On average, equities analysts expect that ZIOPHARM Oncology will post ($0.56) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/08/19/ziopharm-oncology-ziop-earning-somewhat-positive-media-coverage-report-shows-updated-updated.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Insider Buying and Selling by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

What are top analysts saying about ZIOPHARM Oncology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ZIOPHARM Oncology Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit